Printer Friendly

Techedge Board Has Approved for Its New Name as China Biopharma Inc.

ISELIN, N.J. -- Techedge Inc. (OTCBB:TEDG) announced that its board of directors has unanimously approved to change its name to the new name as China Biopharma Inc.

"We have finally transitioned our old business operation to the biopharmaceutical business operation in China. It is a right time to change our name. This proposed new name would be more accurately reflect our current business operation as we are a leading developer, producer and distributor of vaccine products in China. We are ready to distribute flu vaccines as the flu season in China is fast approaching" Peter Wang, CEO of Techedge Inc. stated.

About Techedge, Inc.

Techedge, Inc. is a fast growing developer, producer, and distributor of biopharmaceutical products in China. It has wholly owned subsidiary, China Biopharma Limited and owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd ("ZTB"). The Company's current products consist of human vaccines against influenza, epidemic hemorrhagic fever (HFV), and Japanese Encephalitis (JEV) with high reputation and market shares among Chinese made vaccines. Through its investment and ownership of leading Chinese biopharmaceutical companies, the company plans to build the most efficient and most profitable biopharmaceutical company in China by introducing the most advanced technology, best product, and experienced management team. With a fast growing market, newly completed production facility, and several other new vaccines in the pipeline, it is expected to have a steady business growth.


Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

For more information, please visit its website at
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 6, 2006
Previous Article:Iteris Secures $1 Million Contract from the San Francisco Bay Area Metropolitan Transportation Commission; New Contract Extension Continues to...
Next Article:The Wet Seal, Inc. Announces June Comparable Store Sales and Stock Repurchase Program Activity.

Related Articles
Techedge Signs Letter of Intent to Acquire China BioPharma Limited.
Ludlow Capital Initiates Coverage on China BioPharma's Influenza Vaccine Research.
Techedge, Inc. Appoints Dr. Shu as CEO and Chief Scientist for China BioPharma.
Techedge Inc. Signs Definitive Agreement to Acquire China BioPharma Ltd.
China BioPharma Appoints Dr. Yimin Yu, Current Chairman of HYTE Research to Advisory Board.
China BioPharma Appoints Mr. Shenqian Nie, the CEO of CITIC Pharmaceutical to the Independent Board of Directors.
China BioPharma Issues Profile on
China BioPharma Ltd. Signs Letter of Intent to Acquire Hainan CITIC Biopharmaceutical, China's Largest Vaccine Distributor.
China BioPharma Held Sales Meeting for the Upcoming Flu Season.
Techedge Inc. Projects $10,000,000 in Sales for 2006.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters